Jimin Health Management Co., Ltd. (hereinafter referred to as the "Company") is a modern pharmaceutical enterprise founded in 1996. It is a key backbone enterprise in the pharmaceutical industry in Zhejiang Province and a national high-tech enterprise. The company was launched on the Shanghai Stock Exchange in February 2015. Listed (603222.SH). The company is located in the Zhejiang Huangyan High-tech Development Park, covering an area of ​​nearly 400 acres and has a total number of employees reaching more than 2,000.

Since its listing, the company has actively deployed its "big health strategy". It covers three major sectors: medical and health services, medical devices and chemical and pharmaceuticals, and has initially built a strategic pattern of "one main and two wings" dominated by medical devices and coordinated development of medical services and chemical and pharmaceuticals.

Medical devices are the core business segment of Jimin Health. The products include safe injection puncture device series, pre-charge catheter flusher series, in vitro diagnostic series and hemodialysis concentrate series. Among them, safe injection puncture device series products are internationally , and both are in the leading position in China. The company has been engaged in the injection and puncture device business for more than 30 years and is a leading enterprise in the domestic safety syringe segment. Its main products include safety syringes, safety injection needles, sterile syringes, infusion devices and other products. The company's new product, pre-filled catheter irrigator, is a clinical application product combining medicine and equipment. This product is mainly used in the maintenance of vascular access devices such as PICC (central venous catheterization through peripheral venous ventricular puncture), venous indwelling needles. Its operation is simple and has a wide range of applications, can reduce the consumption of multiple materials, reduce hospital infection risks, reduce needle stab injuries, avoid medication errors, improve safety, improve work flow and efficiency, etc., and has gradually become a traditional saline and heparin dilution solution. Excellent alternative to flushing tube liquid. The company's hemodialysis concentrate series products adopt ultrapure water production process that far exceeds the technical indicators of dialysis water, C+A cleanliness production environment, and automated production equipment to effectively ensure product quality.

The company's wholly-owned subsidiary, Spain LINEAR, has seven major product lines including a variety of diagnostic reagents, laboratory instruments and in vitro diagnostic medical products. Its core products, FOB fecal occult blood automatic immune monitoring and Helicobacter pylori detection kit, have a strong market. Competitiveness.

There are 2 comprehensive hospitals in the medical and health service sector (Boao International Hospital and Ezhou Second Hospital), and they have cooperated with many hospitals in hemodialysis business. In the future, the company will continue to plan comprehensive and specialized (oncology, kidney disease, etc.) hospitals, and is committed to building the company into a big health industry group.

There are nearly 40 infusion varieties in the chemical pharmaceutical sector, and they have various products such as balance, nutrition, therapeutic infusion and external irrigation agents.

Currently, the company has three major production bases in Zhejiang, Shanghai and Spain, and has 6 wholly-owned or controlled subsidiaries: Hainan Jimin Boao International Hospital Co., Ltd., Ezhou Second Hospital Co., Ltd., Renia Chemical Co., Ltd., Jumin Biology Technology Co., Ltd., Zhejiang Jimintang Pharmaceutical Trading Co., Ltd., Taizhou Jurui Plastic Technology Co., Ltd.